CO2020005944A2 - Compuestos heterocíclicos sustituidos con amina como inhibidores de ehmt2, sales de los mismos, y métodos de síntesis de los mismos - Google Patents
Compuestos heterocíclicos sustituidos con amina como inhibidores de ehmt2, sales de los mismos, y métodos de síntesis de los mismosInfo
- Publication number
- CO2020005944A2 CO2020005944A2 CONC2020/0005944A CO2020005944A CO2020005944A2 CO 2020005944 A2 CO2020005944 A2 CO 2020005944A2 CO 2020005944 A CO2020005944 A CO 2020005944A CO 2020005944 A2 CO2020005944 A2 CO 2020005944A2
- Authority
- CO
- Colombia
- Prior art keywords
- substituted heterocyclic
- methods
- amine
- synthesis
- salts
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/32—One oxygen, sulfur or nitrogen atom
- C07D239/42—One nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyridine Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762573917P | 2017-10-18 | 2017-10-18 | |
| PCT/US2018/056428 WO2019079540A1 (en) | 2017-10-18 | 2018-10-18 | AMINO-SUBSTITUTED HETEROCYCLIC COMPOUNDS AS INHIBITORS OF EHMT2, SALTS THEREOF, AND METHODS OF SYNTHESIS THEREOF |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CO2020005944A2 true CO2020005944A2 (es) | 2020-07-31 |
Family
ID=66173899
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CONC2020/0005944A CO2020005944A2 (es) | 2017-10-18 | 2020-05-15 | Compuestos heterocíclicos sustituidos con amina como inhibidores de ehmt2, sales de los mismos, y métodos de síntesis de los mismos |
Country Status (16)
| Country | Link |
|---|---|
| US (2) | US20200247790A1 (https=) |
| EP (1) | EP3697762A4 (https=) |
| JP (2) | JP2021500334A (https=) |
| KR (1) | KR20200101330A (https=) |
| CN (1) | CN111417628A (https=) |
| AU (2) | AU2018353122B2 (https=) |
| BR (1) | BR112020007632A2 (https=) |
| CA (1) | CA3079273A1 (https=) |
| CL (1) | CL2020001009A1 (https=) |
| CO (1) | CO2020005944A2 (https=) |
| EA (1) | EA202090959A1 (https=) |
| IL (2) | IL301746B2 (https=) |
| MA (1) | MA50418A (https=) |
| MX (2) | MX2020007152A (https=) |
| SG (1) | SG11202003225YA (https=) |
| WO (1) | WO2019079540A1 (https=) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11225487B2 (en) | 2017-02-17 | 2022-01-18 | Trevena, Inc. | 7-membered aza-heterocyclic containing δ-opioid receptor modulating compounds, methods of using and making the same |
| CN110621316B (zh) | 2017-04-21 | 2024-01-26 | Epizyme股份有限公司 | 用ehmt2抑制剂进行的组合疗法 |
| KR20240152947A (ko) | 2017-10-18 | 2024-10-22 | 인사이트 코포레이션 | Pi3k-감마 저해제로서의 3차 하이드록시기로 치환된 축합된 이미다졸 유도체 |
| CR20250050A (es) | 2018-09-05 | 2025-03-19 | Incyte Corp | Formas cristalinas de un inhibidor de fosfoinositida 3–quinasa (pi3k) (divisional 2021-0165) |
| CN114249785B (zh) * | 2020-09-23 | 2024-04-05 | 常州方圆制药有限公司 | 一种2-腺苷n-吡唑的衍生物瑞加德松的制备方法 |
| JP2023546729A (ja) * | 2020-10-27 | 2023-11-07 | トレベナ・インコーポレイテッド | デルタオピオイドモジュレーターの結晶形及び非晶形 |
| WO2025240956A1 (en) * | 2024-05-17 | 2025-11-20 | Yale University | G9a/ehmt2 inhibitor use for prader-willi syndrome |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MXPA06003054A (es) * | 2003-09-18 | 2006-05-31 | Novartis Ag | 2,4-di-(fenil-amino)-pirimidinas utiles en el tratamiento de trastornos proliferativos. |
| US8604042B2 (en) * | 2005-11-01 | 2013-12-10 | Targegen, Inc. | Bi-aryl meta-pyrimidine inhibitors of kinases |
| CN103626742B (zh) * | 2005-11-01 | 2017-04-26 | 塔格根公司 | 激酶的联-芳基间-嘧啶抑制剂 |
| US9284272B2 (en) * | 2014-03-28 | 2016-03-15 | Abbvie Inc. | Inhibitors of histone methyltransferase G9a |
| DK3154957T3 (da) * | 2014-06-16 | 2020-02-17 | Fundacion Para La Investig Medica Aplicada | Hidtil ukendte forbindelser som dobbelte inhibitorer af histonmethyltransferaser og dna-methyltransferaser |
| EP3157524A4 (en) * | 2014-06-23 | 2017-12-06 | Genentech, Inc. | Methods of treating cancer and preventing cancer drug resistance |
| HUE064145T2 (hu) * | 2016-04-15 | 2024-03-28 | Epizyme Inc | Amin-szubsztituált aril- vagy heteroaril vegyületek, mint EHMT1 és EHMT2 inhibitorok |
| ES2955132T3 (es) * | 2016-12-19 | 2023-11-28 | Epizyme Inc | Compuestos heterocíclicos sustituidos con amina como inhibidores de EHMT2 y métodos de uso de los mismos |
| EP3600318A4 (en) * | 2017-03-31 | 2021-06-09 | Epizyme, Inc. | METHOD OF USING EHMT2 INHIBITORS |
| EP3697420A4 (en) * | 2017-10-18 | 2021-11-24 | Epizyme, Inc. | METHOD OF USING EHMT2 INHIBITORS IN IMMUNOTHERAPY |
-
2018
- 2018-10-18 CA CA3079273A patent/CA3079273A1/en active Pending
- 2018-10-18 BR BR112020007632-5A patent/BR112020007632A2/pt unknown
- 2018-10-18 MA MA050418A patent/MA50418A/fr unknown
- 2018-10-18 WO PCT/US2018/056428 patent/WO2019079540A1/en not_active Ceased
- 2018-10-18 EP EP18869308.9A patent/EP3697762A4/en not_active Withdrawn
- 2018-10-18 AU AU2018353122A patent/AU2018353122B2/en active Active
- 2018-10-18 KR KR1020207013781A patent/KR20200101330A/ko not_active Ceased
- 2018-10-18 EA EA202090959A patent/EA202090959A1/ru unknown
- 2018-10-18 CN CN201880077022.4A patent/CN111417628A/zh active Pending
- 2018-10-18 US US16/756,565 patent/US20200247790A1/en not_active Abandoned
- 2018-10-18 SG SG11202003225YA patent/SG11202003225YA/en unknown
- 2018-10-18 JP JP2020521599A patent/JP2021500334A/ja not_active Withdrawn
- 2018-10-18 IL IL301746A patent/IL301746B2/en unknown
- 2018-10-18 MX MX2020007152A patent/MX2020007152A/es unknown
-
2020
- 2020-04-15 CL CL2020001009A patent/CL2020001009A1/es unknown
- 2020-04-16 IL IL273974A patent/IL273974B2/en unknown
- 2020-05-15 CO CONC2020/0005944A patent/CO2020005944A2/es unknown
- 2020-07-13 MX MX2024012124A patent/MX2024012124A/es unknown
-
2022
- 2022-03-24 US US17/703,155 patent/US20220324851A1/en not_active Abandoned
-
2023
- 2023-01-11 JP JP2023002371A patent/JP2023036991A/ja active Pending
-
2024
- 2024-02-22 AU AU2024201165A patent/AU2024201165A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| IL301746A (en) | 2023-05-01 |
| CN111417628A (zh) | 2020-07-14 |
| BR112020007632A2 (pt) | 2020-09-29 |
| SG11202003225YA (en) | 2020-05-28 |
| EP3697762A4 (en) | 2021-04-07 |
| JP2023036991A (ja) | 2023-03-14 |
| IL301746B2 (en) | 2025-01-01 |
| CL2020001009A1 (es) | 2020-12-18 |
| MX2024012124A (es) | 2025-02-10 |
| IL301746B1 (en) | 2024-09-01 |
| MA50418A (fr) | 2021-04-07 |
| US20220324851A1 (en) | 2022-10-13 |
| AU2024201165A1 (en) | 2024-03-14 |
| EP3697762A1 (en) | 2020-08-26 |
| IL273974B1 (en) | 2023-04-01 |
| MX2020007152A (es) | 2020-12-10 |
| CA3079273A1 (en) | 2019-04-25 |
| AU2018353122B2 (en) | 2023-11-23 |
| IL273974B2 (en) | 2023-08-01 |
| IL273974A (en) | 2020-05-31 |
| WO2019079540A1 (en) | 2019-04-25 |
| KR20200101330A (ko) | 2020-08-27 |
| AU2018353122A1 (en) | 2020-06-04 |
| US20200247790A1 (en) | 2020-08-06 |
| JP2021500334A (ja) | 2021-01-07 |
| EA202090959A1 (ru) | 2020-07-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO2019006787A2 (es) | Compuestos heterocíclicos sustituidos con amina como inhibidores de ehmt2 y métodos de uso de los mismos | |
| CO2020005944A2 (es) | Compuestos heterocíclicos sustituidos con amina como inhibidores de ehmt2, sales de los mismos, y métodos de síntesis de los mismos | |
| CL2023002682A1 (es) | Uso de inhibidores de ehmt2 para tratar trastornos sanguíneos | |
| CO2018012181A2 (es) | Compuestos arilo o heteroarilo sustituidos con amino como inhibidores de ehmt1 y ehmt2 | |
| BR112015021983A2 (pt) | compostos heterocíclicos e usos dos mesmos | |
| CL2018000318A1 (es) | Compuestos derivados de piridinona, inhibidores de bromodominio; composición farmacéutica que los comprende; y su uso en el tratamiento de enfermedades del cáncer. (solicitud divisional 201600925) | |
| MX384521B (es) | Compuestos de benceno substituidos con arilo o heteroarilo. | |
| AR093244A1 (es) | Compuestos de benceno sustituidos utilizables en el tratamiento de trastornos mediados por ezh2 | |
| CU20160052A7 (es) | Amino-heteroaril-benzamidas como inhibidores de cinasa | |
| BR112018005497A2 (pt) | compostos heterocíclicos e usos dos mesmos | |
| MX2018000179A (es) | Formas solidas y formulaciones de (s)-4-(8-amino-3-(1-(but-2-inoil )pirrolidin-2-il)imidazo[1,5-a]pirazin-1-il)-n-(piridin-2-il)benz amida. | |
| MX2015004771A (es) | Metodos para tratar cancer. | |
| EA201990388A1 (ru) | Пиперидиновые модуляторы рецепторов cxcr7 | |
| EA201592068A1 (ru) | Ингибиторы энхансера zeste гомолога 2 | |
| BR112015030515A2 (pt) | intensificadores de inibidores de homólogo 2 de zeste | |
| DOP2018000062A (es) | Piridinona dicaboxamidas para uso como inhibidores de bromodominio | |
| AR100431A1 (es) | Compuestos de pladienolida piridina y métodos de uso | |
| TR201908265T4 (tr) | Isı şok transkripsiyon faktörü 1 in inhibitörleri olarak kaynaşık 1,4-dihidrodioksin türevleri. | |
| AU2017269673A1 (en) | Pyridine dicarboxamide derivatives as bromodomain inhibitors | |
| BR112017005242A2 (pt) | composto, composição farmacêutica, e, composto para uso. | |
| BR112017028616A2 (pt) | acentuador de inibidores de homólogo de zeste 2 | |
| MX2018002898A (es) | Compuestos utiles para inhibir ror-gamma-t. | |
| UY37191A (es) | Derivados de dibenzofurano para uso como inhibidores de bromodominio | |
| EA201600394A1 (ru) | Трициклические соединения пиперидина | |
| UY38006A (es) | Inhibidores de la quinasa mtor, composiciones farmacéuticas que los contienen, y al uso en terapia de tales compuestos y composiciones |